Holding(s) in Company

RNS Number : 1610Q

Advanced Oncotherapy PLC

17 June 2020

 

17 June 2020

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Holding(s) in Company

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has been informed that Mr Seamus Mulligan has a total beneficial interest in 30,405,721 ordinary shares of 25p each in the Company ("Ordinary Shares"), representing 9.92% of the Company's issued share capital. Mr Mulligan's interest is held as to 22,500,000 Ordinary Shares by Nerano Capital Limited (a 100% subsidiary of Nerano Pharma Limited) and 7,905,721 Ordinary Shares by Barrymore Investments Limited.

Advanced Oncotherapy plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Allenby Capital Limited  (Nomad & Broker)
Nick Athanas / Liz Kirchner / Nicholas Chambers	Tel: [phone]
FTI Consulting  (Financial PR & IR)	[e-mail]
Simon Conway / Rob Winder	Tel: [phone]

Notes for Editors

About Advanced Oncotherapy Plc  www.avoplc.com

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

HOLUNAWRRBUNAAR